ENCLOSURE 5

NRC FORM 591M PART 1 (10-2003) 10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Missouri Baptist medical Center **3015 N Ballas Road** **St. Louis, MO 63131** *REPORT 2006/001*	**Nuclear Regulatory Commission** **Region III** **2443 Warrenville Road, Suite 210** **Lisle, Illinois 60532**

3. DOCKET NUMBER(S)	4. LICENSEE NUMBER(S)	5. DATE(S) OF INSPECTION
030-08325	**24-11128-02**	**04/26/2006**

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

[X] 1. Based on the inspection findings, no violations were identified.

[ ] 2. Previous violation(s) closed.

[ ] 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy to exercise discretion, were satisfied.

_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

[ ] 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	**Tony Go**	Tony Go	**04/26/2006**

NRC FORM 591M PART 3
(10-2003) 10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

DOCKET FILE INFORMATION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE	2. NRC/REGIONAL OFFICE
Missouri Baptist Medical Center REPORT 2006/001	**Region III**

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-08325	**24-11128-02**	**04/ 26 /06**

6. INSPECTION PROCEDURES	7. INSPECTION FOCUS AREAS
87131, 87132	**03.01 - 03.07**

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
2230	2	***Thomas Moenster***	314-996-5397

X	Main Office Inspection	Next Inspection Date: 04/08
	Field	
	Temporary	

PROGRAM SCOPE

The licensee is a 300-bed medical facility located in St. Louis, MO. The licensee is authorized to use byproduct materials per 10 CFR 35.100, 35.200, 35.300, and 35.400. In addition, the licensee is authorized for 10 CFR 35.600, a high-dose-rate remote afterloading brachytherapy device. The approved HDR device is the Varian GammaMed Model-12it (portable unit).

Currently, the licensee's authorized (19) users (MDs), a department manager, and a crew of physicists and dosimetrists (a group of consultants). In 2005, the licensee performed approximately 59 HDR treatments of multiple fractions each. The licensee oncology department also performed approximately 113 permanent prostate implants using I-125 seeds, and on occasion, the licensee performed low dose LDR brachytherapies using Cs-137 tubes (only one therapy in 2003).

The Nuclear Medicine department performed 47diagnostic studies per day, and radiopharmaceutical therapies. Specifically, the licensee's staff administered 68 hyperthyroid therapies per year using I-131 capsules with doses greater than 5 mCi, and approximately less than 24 ablation therapies per year with capsules containing 100 and 200 mCi of I-131. The licensee orders unit doses from a radiopharmacy. The licensee employed eight technologists for the NM department.

Performance Observations

During the inspection, the licensee's nuclear medicine staff demonstrated: (1) a daily radiation survey; (2) a weekly removable contamination survey; (3) a survey of a package; and (4) a daily dose calibrator constancy check. The inspector observed a diagnostic administration and the HDR daily QA tests during the inspection. The inspector reviewed written directives for iodine-131, HDR treatments and as well permanent seed implants using I-125 seeds. No violations were identified during the inspections of the facilities. The records indicated that the licensee had conducted multiple fractions of gynecological and lung therapies with the HDR unit. The HDR unit was found stored in the licensee secured storage room, the licensee's HDR unit is currently owned by the physics group and shared with other hospitals. The HDR unit maintenance record was also reviewed during the inspection, and no safety problem was identified during the quarterly preventive maintenance. The inspector noted that the room formerly teletherapy facility contains all the safety systems, and it is located within the department as indicated by the license.